Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: Opportunities and challenges

Alzheimer's and Dementia

Volumn 5, Issue 2, 2009, Pages 166-171

  Ringman, John M ^a   Grill, Joshua ^a   Rodriguez Agudelo, Yaneth ^b   Chavez, Mireya ^b   Xiong, Chengjie ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; NOOTROPIC AGENT; SIMVASTATIN;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; EDITORIAL; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HETEROZYGOTE DETECTION; HIGH RISK PATIENT; HUMAN; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PREVENTION STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; RESEARCH ETHICS; RESEARCH SUBJECT; RISK ASSESSMENT;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DISEASE PROGRESSION; DRUG DESIGN; GENES, DOMINANT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; RISK REDUCTION BEHAVIOR;

EID: 62849113301     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2008.12.002     Document Type: Editorial

References (29)

1. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
2. Fox N.C., Warrington E.K., Seiffer A.L., Agnew S.K., and Rossor M.N. Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease: a longitudinal prospective study. Brain 121 (1998) 1631-1639
3. Ringman J.M., Diaz-Olavarrieta C., Rodriguez Y., Chavez M., Fairbanks L., Paz F., et al. Neuropsychological function in pre-clinical presenilin-1 mutation carriers. Neurology 60 (2003) A453
4. Schott J.M., Fox N.C., Frost C., Scahill R.I., Janssen J.C., Chand D., et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 53 (2003) 181-188
5. Kennedy A.M., Frackowiak R.S., Newman S.K., Bloomfield P.M., Seaward J., Roques P., et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 186 (1995) 17-20
6. Ringman J.M., O'Neill J., Geschwind D., Medina L., Apostolova L.G., Rodriguez Y., et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 130 (2007) 1767-1776
7. Moonis M., Swearer J.M., Dayaw M.P., St George-Hyslop P., Rogaeva E., Kawarai T., et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 65 (2005) 323-325
8. Ringman J.M., Younkin S.G., Pratico D., Seltzer W., Cole G.M., Geschwind D.H., et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71 (2008) 85-92
9. Brookmeyer R., Gray S., and Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88 (1998) 1337-1342
10. Kawas C.H. Medications and diet: protective factors for AD?. Alzheimer Dis Assoc Disord 20 (2006) S89-S96
11. DeKosky S.T., Fitzpatrick A., Ives D.G., Saxton J., Williamson J., Lopez O.L., et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 27 (2006) 238-253
12. Launer L.J. Prevention of AD: the which, when, and on whom?. Alzheimer Dis Assoc Disord 20 (2006) S75-S78
13. Thal L.J. Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord 20 (2006) S97-S99
14. Shumaker S.A., Legault C., Kuller L., Rapp S.R., Thal L., Lane D.S., et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291 (2004) 2947-2958
15. Kryscio R.J., Mendiondo M.S., Schmitt F.A., and Markesbery W.R. Designing a large prevention trial: statistical issues. Stat Med 23 (2004) 285-296
16. Cummings J.L., Doody R., and Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 69 (2007) 1622-1634
17. Fox N.C., Kennedy A.M., Harvey R.J., Lantos P.L., Roques P.K., Collinge J., et al. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene: pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 120 (1997) 491-501
18. Murrell J., Ghetti B., Cochran E., Macias-Islas M.A., Medin L., Varpetian A., et al. The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 7 (2006) 277-279
19. Ezquerra M., Lleo A., Castellvi M., Queralt R., Santacruz P., Pastor P., et al. A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. Arch Neurol 60 (2003) 1149-1151
20. Rossor M.N., Fox N.C., Beck J., Campbell T.C., and Collinge J. Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation. Lancet 347 (1996) 1560
21. Schenk D.B., Seubert P., Grundman M., and Black R. A beta immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis 2 (2005) 255-260
22. Ridha B.H., Barnes J., Bartlett J.W., Godbolt A., Pepple T., Rossor M.N., et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 5 (2006) 828-834
23. Xiong C, Zhu K, Yu K, Miller JP. Statistical modeling in biomedical research: longitudinal data analysis. In: Rao CR, Miller JP, Rao DC, eds. Handbook of Statistics: Epidemiology and Medical Statistics. Amsterdam: Elsevier, 2007, p.429-63.
24. Cummings J.L. Optimizing phase II of drug development for disease-modifying compounds. Alzheimers & Dementia 4 (2008) S15-S20
25. Czirr E., Leuchtenberger S., Dorner-Ciossek C., Schneider A., Jucker M., Koo E.H., et al. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J Biol Chem 282 (2007) 24504-24513
26. Margolis R.L., and Ross C.A. Diagnosis of Huntington disease. Clin Chem 49 (2003) 1726-1732
27. Goizet C., Lesca G., and Durr A. Presymptomatic testing in Huntington's disease and autosomal dominant cerebellar ataxias. Neurology 59 (2002) 1330-1336
28. Steinbart E.J., Smith C.O., Poorkaj P., and Bird T.D. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 58 (2001) 1828-1831
29. Hinerfeld D.A., Moonis M., Swearer J.M., Baker S.P., Caselli R.J., Rogaeva E., et al. Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. Arch Neurol 64 (2007) 1672-1673